Silence Therapeutics (SLN) Operating Margin (2020 - 2025)
Historic Operating Margin for Silence Therapeutics (SLN) over the last 6 years, with Q3 2025 value amounting to 16505.66%.
- Silence Therapeutics' Operating Margin fell 145031900.0% to 16505.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 321.21%, marking a year-over-year increase of 438600.0%. This contributed to the annual value of 146.38% for FY2024, which is 570900.0% up from last year.
- According to the latest figures from Q3 2025, Silence Therapeutics' Operating Margin is 16505.66%, which was down 145031900.0% from 10697.77% recorded in Q2 2025.
- Silence Therapeutics' Operating Margin's 5-year high stood at 0.0% during Q4 2021, with a 5-year trough of 20006.34% in Q1 2025.
- For the 5-year period, Silence Therapeutics' Operating Margin averaged around 2938.7%, with its median value being 389.23% (2021).
- Per our database at Business Quant, Silence Therapeutics' Operating Margin surged by 6546400bps in 2021 and then tumbled by -199707900bps in 2025.
- Silence Therapeutics' Operating Margin (Quarter) stood at 0.0% in 2021, then crashed by -183833048bps to 230.03% in 2022, then tumbled by -175bps to 633.59% in 2023, then skyrocketed by 97bps to 17.2% in 2024, then tumbled by -95873bps to 16505.66% in 2025.
- Its last three reported values are 16505.66% in Q3 2025, 10697.77% for Q2 2025, and 20006.34% during Q1 2025.